Spiramycin-chitosan Nanoparticles Decline Parasite Burden and Renovate Patent Histopathological Changes in Liver and Lung in Mice Experimentally Infected with Acute Toxoplasmosis | Nadia El-Dib

Spiramycin-chitosan Nanoparticles Decline Parasite Burden and Renovate Patent Histopathological Changes in Liver and Lung in Mice Experimentally Infected with Acute Toxoplasmosis

Citation:: Osama, D., N. A. El-Dib, K. H.M, and H. Ibrahim, Spiramycin-chitosan Nanoparticles Decline Parasite Burden and Renovate Patent Histopathological Changes in Liver and Lung in Mice Experimentally Infected with Acute Toxoplasmosis, , 2024.

Preview	Attachment	Size
	jesp_volume_53_issue_3_pages_569-574.pdf	1.03 MB